10 results about "Genetic profile" patented technology

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

A computer-implemented method for training a predictive model to predict a probability that an initial state of a subject will develop a subsequent state. The method includes receiving sequence reads, grouping the sequencing reads into families, constructing a molecular state vector for subjects, storing ordered pairs of vectors, and training the predictive model based on the ordered pairs of vectors. The system supports training the predictive model on a genetic profile of a tumor, a patient profile, and / or treatment profiles.

This provides a method to reduce cardiovascular risk in patients with a genetic profile associated with a response to proprotein converter subtilisin / kexin type 9 (PCSK9) inhibitor therapy. [Solution] A method for treating a patient at risk of major cardiovascular adverse events (MACE) includes: determining the patient's polygenetic risk score (CAD-PRS), which includes a weighted sum of multiple gene variants associated with coronary artery disease; identifying the patient as being at high risk of MACE if the patient has a CAD-PRS greater than a threshold CAD-PRS determined from a reference population; and administering a PCSK9 inhibitor to the patient if the patient has been identified as being at high risk of MACE.

The present disclosure relates generally to methods for preparing spatial proteome and / or transcriptome sequencing libraries from biological samples, which in some embodiments are useful for determining genetic profiles, aiding in the diagnosis of subjects having or at risk of having a disorder, and improving treatment of subjects.

A system for providing a personal care recommendation, and techniques for generating personal skin care recommendations, are provided. Example systems may include one or more processors and a diagnostic device to detect a personal care condition. The processors can assess a genetic profile of a user of the system and predict changes in the personal care condition based on the genetic profile and on information provided by the diagnostic device. The processors can generate the personal care recommendation based on the personal care condition or predicted changes in the personal care condition. A user interface coupled to the one or more processors can provide the generated personal care recommendation to the user.

The present disclosure provides methods of determining whether or not to administer a subject gabapentin, said method comprising assessing the genetic profile of a subject considered for a gabapentin-based therapy and determining, on the basis of the genetic profile, whether or not to administer the subject gabapentin.

The present invention provides a method for precision anti-obesity therapy, utilizing a proprietary panel of genetic variants to predict individual patient response to weight-loss medications as well as a related companion diagnostic. In particular, the method analyzes variants in genes including GLP-1 R, CNR1, TCF7L2, DPP4 and others, which have established associations with drug efficacy and metabolism in obesity treatment. By genotyping these markers, the method guides selection and dose optimization of specific anti-obesity medications—such as GLP-1 receptor agonists, metformin, SGLT2 inhibitors, and DPP4 inhibitors—tailored to the patient's genetic profile. Notably, GLP-1R polymorphisms (e.g., rs6923761) are leveraged as especially predictive indicators of enhanced weight loss response to GLP-1 receptor agonists. Through this innovative genetic profiling approach, the invention enables personalized treatment strategies that maximize efficacy, minimize trial-and-error in drug choice, and reduce adverse effects, thereby embodying the principles of precision medicine in obesity care.

The present disclosure relates, in general, to methods for improving preparation of a spatial transcriptomics RNA, library, for example a mRNA library, by improving capture of RNA transcript information from a tissue sample in situ. The spatial transcriptomics library from a tissue sample is useful to determine a genetic profile and help diagnose a person who has or is at risk of having a disease, such as cancer, genetic disease, autoimmune disease, and other indications, and improve treatment of the subject.

The present disclosure generally relates to methods for improving the preparation of spatial transcriptomics RNA libraries, such as mRNA libraries, by improving the capture of RNA transcript information from tissue samples in situ. Spatial transcriptomics libraries from tissue samples are useful for determining genetic profiles, aiding in the diagnosis of individuals having or at risk of having diseases such as cancer, genetic diseases, autoimmune diseases, and other indications, and for improving treatment of subjects.

The present disclosure relates, in general, to methods of preparing a spatial proteome and / or transcriptome sequencing library. The spatial proteome and / or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.